Human fungal pathogen Candida albicans cannot utilize L‐sorbose as a sole carbon source. However, chromosome 5 monosomic strains can grow on sorbose as repressors present on this chromosome get diminished allowing the expression of sorbose utilization gene (SOU1) located on chromosome 4. Functional identification of these repressors has been a difficult task as they are scattered on a large portion of the right arm of chromosome 5. Herein, we have applied the telomere‐mediated chromosomal truncation approach to identify a novel repressor for sorbose utilization in this pathogen. Multiple systematic chromosomal truncations were performed on the right arm of Chr5 in the background of csu51∆/CSU51 to minimize the functional region to 6‐kb chromosomal stretch. Further, truncation that removes the part of Orf19.3942 strongly suggested its role in sorbose utilization. However, compelling evidence comes from the observation that truncation at 1,044.288‐kb position of Chr5 in the strain csu51∆/CSU51 orf19.3942∆/Orf.19.3942 produced Sou+ phenotype; otherwise, the strain remains Sou−. This confirms beyond doubt the role of Orf.19.3942 in the regulation of sorbose utilization and designated as CSU57. Comparison of SOU1 gene expression of Sou+ strains with wild type suggested its role at transcriptional level. Strain carrying double disruption of CSU57 remains Sou−. Co‐overexpression of SOU1 and CSU57 together does not make the recipient strain Sou−; however, multiple tandem copies of CSU57 produced diminished growth compared with control suggesting that it is a weak repressor. Taken together, we report that CSU57 encodes a novel repressor of L‐sorbose utilization in this pathogen. TAKE AWAY CSU57 encodes a repressor for L‐sorbose utilization in Candida albicans. Csu57p acts in combination with Csu51p and other regulators. Csu57p exerts its repressing effect at transcriptional level of SOU1 gene. Utilization of sorbose positively correlates to the expression of SOU1 gene. Multiple copies of CSU57 can partially suppress Sou+ phenotype.

The upsurge of immunocompromised patients has led to extensive study of fungal infections with Candida albicans being the frontline model of pathogenic yeast in humans. In the quest to find novel antifungal agents, this study reports the potential usage of wild-type C. albicans strain C86 to biosynthesise silver nanoparticles by microwave assisted technique. Visual colour change and UV-spectrophotometer were used for primary detection of silver nanoparticles. Additionally, the FTIR peaks confirm the particles’ formation and surface characterisation techniques such as FESEM and EDX suggests that the silver nanoparticles were sized in the range of 30–70 nm. Furthermore, pioneering work of homologous recombination technique was systematically employed to delete uncharacterized gene orf19.3120 (CNP41) in the C86 strain creating the deletion strain C403 of C. albicans. To amalgamate the two significant findings, biosynthesized silver nanoparticles were subjected to antifungal studies by disk diffusion assay on the strain C403 that lacks the gene orf19.3120 (CNP41) of C. albicans. As a synergetic approach, combinational effect was studied by incorporating antifungal drug fluconazole. Both individual and enhanced combinational antifungal effects of silver nanoparticles and fluconazole were observed on genetically modified C403 strain with 40% increase in fold area compared to wild-type C86 strain. This can be attributed to the synergetic effect of the bonding reaction between fluconazole and AgNPs. Taken together, this first-ever interdisciplinary study strongly suggests that the CNP41 gene could play a vital role in drug resistance in this fungal pathogen.

Background Candida albicans is an opportunistic human fungal pathogen responsible for superficial and systemic life-threatening infections. Treating these infections is challenging as many clinical isolates show increased drug resistance to antifungals. Chromosome (Chr) 4 monosomy was implicated in a fluconazole-resistant mutant. However, exposure to fluconazole adversely affects Candida cells and can generate numerous mutations. Hence, the present study aimed to truncate Chr4 and challenge the generated Candida strains to antifungals and evaluate their role in drug response. Results Herein, Chr4 was truncated in C. albicans using the telomere-mediated chromosomal truncation method. The resulting eight Candida strains carrying one truncated homolog of Chr4 were tested for response to multiple antifungals. The minimal inhibitory concentration (MIC) for these strains was determined against three classes of antifungals. The MIC values against fluconazole, amphotericin B, and caspofungin were closer to that of the wild type strain. Microdilution assay against fluconazole showed that the mutants and wild type strains had similar sensitivity to fluconazole. The disc diffusion assay against five azoles and two polyenes revealed that the zones of inhibition for all the eight strains were similar to those of the wild type. Thus, none of the generated strains showed any significant resistance to the tested antifungals. However, spot assay exhibited a reasonably high tolerance of a few generated strains with increasing concentrations of fluconazole. Conclusion This analysis suggested that Chr4 aneuploidy might not underlie drug resistance but rather drug tolerance in Candida albicans.